No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
PRCT240517P62500
- 0.47
- -0.28-37.33%
15min DelayClose May 14 15:59 ET
0.87High0.47Low
0.87Open0.75Pre Close20 Volume14 Open Interest62.50Strike Price1.35KTurnover54.63%IV-4.76%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.47Time Value100Contract SizeAmericanOptions Type-0.1731Delta0.0811Gamma217.70Leverage Ratio-0.1406Theta-0.0009Rho-37.68Eff Leverage0.0148Vega
Intraday
- 5D
- 1D
News
PROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock Conference
SAN JOSE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solu
Alight, Novavax, and More Stocks See Action From Activist Investors
These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from May 2 through May 8, 2024. Source: VerityData
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT), Amgen (AMGN) and Elevation Oncology (ELEV)
Unveiling 4 Analyst Insights On PROCEPT BioRobotics
4 analysts have shared their evaluations of PROCEPT BioRobotics (NASDAQ:PRCT) during the recent three months, expressing a mix of bullish and bearish perspectives.In the table below, you'll find a sum
PROCEPT BioRobotics Price Target Raised to $75.00/Share From $65.00 by TD Cowen
PROCEPT BioRobotics Price Target Raised to $75.00/Share From $65.00 by TD Cowen
Express News | Piper Sandler Maintains Overweight on PROCEPT BioRobotics, Raises Price Target to $75
Comments
Recent insider selling of PROCEPT BioRobotics shares and lack of insider buying, along with not particularly high insider ownership, raises caution about the company. Consider the company's investment risks before purchasing.
This Insider Has Just Sold Shares In PROCEPT BioRoboticsPROCEPT BioRobotics has a conservative balance sheet and could probably eliminate its debt without much difficulty. Despite losing money over the last twelve months, the company's solid revenue growth may indicate a path to profitability.
Insider selling at PROCEPT BioRobotics' current share price levels doesn't imply major concern nor positivity. Lack of insider purchases in the past year and shares held by insiders, combined with past sales, call for careful investments due to potential company risks.
Upgrades
• $Allogene Therapeutics(ALLO.US$ : Goldman Sachs Upgrades to Buy from Neutral - PT $32 (from $9)
• $ChampionX(CHX.US$ : BofA Securities Upgrades to Buy from Neutral - PT $22 (from $25)
• $CSX Corp(CSX.US$ : Stifel Upgrades to Buy from Hold - PT $37 (from $39)
• $TechnipFMC(FTI.US$ : BofA Securities Upgrades to Buy from Neutral - PT $8 (from $9.50)
• $Norfolk Southern(NSC.US$ : Stifel Upgrades to Buy from Hold - PT $2...
• $Allogene Therapeutics(ALLO.US$ : Goldman Sachs Upgrades to Buy from Neutral - PT $32 (from $9)
• $ChampionX(CHX.US$ : BofA Securities Upgrades to Buy from Neutral - PT $22 (from $25)
• $CSX Corp(CSX.US$ : Stifel Upgrades to Buy from Hold - PT $37 (from $39)
• $TechnipFMC(FTI.US$ : BofA Securities Upgrades to Buy from Neutral - PT $8 (from $9.50)
• $Norfolk Southern(NSC.US$ : Stifel Upgrades to Buy from Hold - PT $2...
14
1
$PROCEPT BioRobotics(PRCT.US$ 50 today?
2
Read more